Welcome to our dedicated page for TenX Keane Acquisition news (Ticker: TENKR), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition stock.
TenX Keane Acquisition (TENKR) provides investors with essential updates on strategic mergers, corporate restructuring, and capital market developments through this centralized news hub. Our curated collection delivers timely press releases and analysis on the company's SPAC activities, offering critical insights for informed decision-making.
Access real-time updates on merger transactions, leadership announcements, and regulatory filings that shape TENKR's position in the capital markets. The resource serves both novice and experienced investors by distilling complex financial strategies into actionable information without speculative commentary.
Key content categories include merger execution updates, corporate restructuring developments, and strategic partnership announcements. Each update maintains strict adherence to factual reporting while contextualizing market implications through an industry-specific lens.
Bookmark this page for continuous access to TENKR's evolving corporate narrative. Combine regular visits with independent research to maintain a comprehensive understanding of the company's SPAC-related activities and market positioning.
TenX Keane Acquisition (Nasdaq: TENKU) faced a trading halt on August 7, 2024, due to additional information requested by Nasdaq following unusual trading activity. The company is working with Nasdaq to lift the halt. Meanwhile, TenX shareholders approved the merger with Citius Oncology on August 2, 2024. The post-merger entity is expected to trade as Citius Oncology, Inc. (CTOR) on Nasdaq.
In a related development, Citius Pharmaceuticals (Nasdaq: CTXR) announced FDA approval for LYMPHIR™, a treatment for relapsed or refractory cutaneous T-cell lymphoma. TenX and Citius Pharma are progressing towards closing the business combination in the near future.
TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.
TenX Keane Acquisition (NASDAQ:TENKU) announced the closing of its initial public offering (IPO) of 6,600,000 units at an offering price of $10.00 per unit, generating $66,000,000 in gross proceeds. The IPO included a partial exercise of the underwriter's over-allotment option for 600,000 units. Each unit consists of one ordinary share and one right, with rights entitling holders to receive two-tenths of one share upon the initial business combination. The units began trading on NASDAQ under the symbol TENKU on October 14, 2022.
TenX Keane Acquisition has successfully priced its initial public offering (IPO) at $10.00 per unit, totaling 6,000,000 units. Each unit includes one ordinary share and a right to receive two-tenths of one ordinary share upon completing the Company's initial business combination. Trading under the ticker symbol TENKU begins on October 14, 2022, on the Nasdaq Global Market. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 900,000 units. The offering is slated to close on October 18, 2022, pending customary closing conditions.
